Teplizumab: an FDA- approved drug, marks milestone in treatment of type 1 diabetes

Abstract

Diabetes type-1 is a chronic disease characterized by immune-mediated destruction of insulin-producing beta cells in the pancreas. It progresses through distinct stages at varying rates, with stage 1 being β-cell autoimmunity with normal blood sugar, stage 2 being β-cell autoimmunity with dysglycemia, and stage 3 being symptomatic disease onset.